Canada Life
RCUS icon

Canada Life’s Arcus Biosciences RCUS Stock Holding History

Canada Life’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.53M Sell
70,518
-3,344
-5% -$72.2K ﹤0.01% 1237
2025
Q4 		$1.76M Buy
73,862
+14,610
+25% +$298K ﹤0.01% 1205
2025
Q3 		$789K Hold
59,252
– – ﹤0.01% 1502
2025
Q2 		$482K Buy
59,252
+7,102
+14% +$60.7K ﹤0.01% 1613
2025
Q1 		$410K Hold
52,150
– – ﹤0.01% 1645
2024
Q4 		$775K Hold
52,150
– – ﹤0.01% 1535
2024
Q3 		$798K Sell
52,150
-6,702
-11% -$106K ﹤0.01% 1570
2024
Q2 		$895K Buy
58,852
+12,426
+27% +$201K ﹤0.01% 1525
2024
Q1 		$876K Hold
46,426
– – ﹤0.01% 1533
2023
Q4 		$886K Hold
46,426
– – ﹤0.01% 1534
2023
Q3 		$834K Buy
46,426
+932
+2% +$18.7K ﹤0.01% 1547
2023
Q2 		$924K Sell
45,494
-3,239
-7% -$61.7K ﹤0.01% 1521
2023
Q1 		$888K Sell
48,733
-4,222
-8% -$80.7K ﹤0.01% 1545
2022
Q4 		$1.09M Sell
52,955
-3,798
-7% -$105K ﹤0.01% 1488
2022
Q3 		$1.48M Buy
56,753
+11,683
+26% +$309K ﹤0.01% 1320
2022
Q2 		$1.14M Buy
45,070
+43,254
+2,382% +$1.06M ﹤0.01% 1422
2022
Q1 		$61K Sell
1,816
-694
-28% -$23.3K ﹤0.01% 2110
2021
Q4 		$101K Hold
2,510
– – ﹤0.01% 2009
2021
Q3 		$88K Hold
2,510
– – ﹤0.01% 2084
2021
Q2 		$69K Hold
2,510
– – ﹤0.01% 2171
2021
Q1 		$70K Sell
2,510
-1,041
-29% -$36.2K ﹤0.01% 2191
2020
Q4 		$92K Buy
3,551
+1,871
+111% +$45.3K ﹤0.01% 2131
2020
Q3 		$29K Hold
1,680
– – ﹤0.01% 2337
2020
Q2 		$41K Buy
1,680
+1,252
+293% +$33.8K ﹤0.01% 2285
2020
Q1 		$6K Hold
428
– – ﹤0.01% 2563
2019
Q4 		$4K Buy
+428
New +$3.6K ﹤0.01% 2625
2019
Q3 		– Sell
-4,956
Closed -$39K – 2011
2019
Q2 		$39K Hold
4,956
– – ﹤0.01% 2502
2019
Q1 		$62K Hold
4,956
– – ﹤0.01% 2208
2018
Q4 		$51K Buy
+4,956
New +$57.9K ﹤0.01% 2369

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Canada Life's RCUS Position: Q1 2026 in Review

Canada Life reduced its Arcus Biosciences (RCUS) stake by 4.5% in Q1 2026, selling an estimated $72.2K and leaving 70,518 shares worth $1.53M. The position accounts for ﹤0.01% of the portfolio, ranked #1237.

Canada Life first reported a position in RCUS in Q4 2018 and has held it in 29 quarters since. The position peaked at $1.76M in Q4 2025. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.

  • Canada Life held 70,518 shares of Arcus Biosciences worth $1.53M as of Q1 2026.
  • Canada Life sold 3,344 Arcus Biosciences shares in Q1 2026, an estimated $72.2K.
  • Arcus Biosciences made up ﹤0.01% of Canada Life's portfolio in Q1 2026, its #1237 holding.
  • Canada Life first reported a position in Arcus Biosciences in Q4 2018 and has held it in 29 quarters since.
  • Canada Life's Arcus Biosciences position peaked at $1.76M in Q4 2025.
  • 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.

Based on Canada Life's 13F filing for Q1 2026, filed 14 May 2026.